Navigation Links
PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
Date:3/9/2010

ANNAPOLIS, Md., March 9 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Company will present at the Roth Capital Partners Growth Stock Conference in Laguna Niguel, California on Monday, March 15, 2010 at 1:30 p.m. P.T. To access the Company's presentation via webcast, go to:  http://www.wsw.com/webcast/roth23/pip/.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

For more information about PharmAthene, please visit www.PharmAthene.com.

SOURCE PharmAthene, Inc.

Back to top

RELATED LINKS
http://www.pharmathene.com

'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
2. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
3. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
4. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
5. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
6. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
7. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
8. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
9. PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
10. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
11. PharmAthenes 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):